(Reuters) - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
/PRNewswire/ - Eisai today announces the expansion of its UK Hatfield based EMEA (Europe, Middle East, Africa, Russia and Oceania) Knowledge Centre with an additional high potency, global packaging capability.
We regularly dig into compensation for top executives, but figures on the biopharma rank and file are harder to come by. So, if you've been waiting for those numbers, here's a taste: MedReps.com has run the numbers on sales people in the medical field. The big winners?
AstraZeneca today announced that its new UK-based global research and development centre and corporate headquarters will be located at the Cambridge Biomedical Campus on the southern outskirts of the city. By 2016, the new site will house a highly-skilled workforce of approximately 2,000.
(BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd.
Qu Biologics has appointed former president of Novartis' US operations Robert Pelzer to its board of directors.
Pelzer was appointed president of Novartis Corporation in 2008, holding responsibility for Novartis' operations in North America.